Amneal Pharmaceuticals Overview
Latest ROE for Amneal Pharmaceuticals: 288.05% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow288.05%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Amneal Pharmaceuticals's return on equity stands at 288.05%. That is above the Healthcare sector average of 11.15%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Amneal Pharmaceuticals sits higher the Healthcare benchmark (11.15%) with a ROE of 288.05%. That is roughly 2482.5% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 288.05% for Amneal Pharmaceuticals means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Amneal Pharmaceuticals's ROE evolved across reporting periods, while the comparison chart places AMRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Amneal Pharmaceuticals's reading of 288.05% (sector avg 11.15%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
